M Weil
Impact in
- Hematology top 2%
- Acute Myeloid Leukemia Research
- Genetics top 5%
- Chronic Lymphocytic Leukemia Research
Papers in
- Oncology 32
- Cancer Treatment and Pharmacology 16
- HER2/EGFR in Cancer Research 6
-
- Acute Lymphoblastic Leukemia research 24
- Co-authors
- M Boiron (30 shared papers)C Jacquillat (23 shared papers)G Auclerc (21 shared papers)J Bernard (24 shared papers)Jean Bernard (7 shared papers)D. Khayat (14 shared papers)J Tanzer (11 shared papers)C Jacquillat (17 shared papers)
- Journals
- Recent results in cancer research (8 papers)Cancer (6 papers)Cancer Chemotherapy and Pharmacology (4 papers)The Lancet (2 papers)European Journal of Cancer (2 papers)
- Partner nations
- FranceUnited StatesAustria
In The Last Decade
M Weil
70 papers receiving 1.1k citations
Peers
Comparison fields: 5 of 75
- Hematology 405
- Genetics 213
- Oncology 489
- Public Health, Environmental and Occupational Health 413
- Pathology and Forensic Medicine 226
Countries citing papers authored by M Weil
This map shows the geographic impact of M Weil's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M Weil with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M Weil more than expected).
Fields of papers citing papers by M Weil
This network shows the impact of papers produced by M Weil. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M Weil. The network helps show where M Weil may publish in the future.
Co-authors
The 25 scholars most cited alongside M Weil, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 76 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 1990 | 194 | |
| 2 | 1983 | 149 | |
| 3 | 1969 | 92 | |
| 4 | Combination therapy in 130 patients with acute lymphoblastic leukemia (protocol 06 LA 66-Paris). | 1973 | 77 |
| 5 | 1988 | 74 | |
| 6 | 1979 | 69 | |
| 7 | 1984 | 66 | |
| 8 | 1976 | 48 | |
| 9 | 1993 | 42 | |
| 10 | 1976 | 42 | |
| 11 | 1980 | 38 | |
| 12 | 1966 | 34 | |
| 13 | [Trial of treatment of acute lymphoblastic and myeloblastic leukemias by a new antibiotic: rubidomycin (RP 13,057). Study of 61 cases]. | 1967 | 24 |
| 14 | 1986 | 22 | |
| 15 | 1978 | 22 | |
| 16 | 1988 | 21 | |
| 17 | 1974 | 19 | |
| 18 | 1969 | 18 | |
| 19 | [Treatment of Hodgkin's disease by polychemotherapy combining nitrogen mustard, vincristine, methylhydrazine and prednisone]. | 1967 | 13 |
| 20 | 1992 | 12 |
About M Weil
M Weil is a scholar working on Oncology, Public Health, Environmental and Occupational Health, Hematology, Molecular Biology and Genetics, having authored 76 papers that have together received 1.3k indexed citations. Recurring topics across this work include Acute Lymphoblastic Leukemia research (24 papers), Acute Myeloid Leukemia Research (17 papers), Cancer Treatment and Pharmacology (16 papers), Chronic Lymphocytic Leukemia Research (11 papers), Lymphoma Diagnosis and Treatment (9 papers), Breast Cancer Treatment Studies (7 papers), Cancer therapeutics and mechanisms (7 papers) and HER2/EGFR in Cancer Research (6 papers). The work is most often cited by research in Hematology (405 citations), Genetics (213 citations), Oncology (489 citations), Public Health, Environmental and Occupational Health (413 citations) and Pathology and Forensic Medicine (226 citations). M Weil has collaborated with scholars based in France, United States and Austria. Frequent co-authors include M Boiron, C Jacquillat, G Auclerc, J Bernard, Jean Bernard, D. Khayat, J Tanzer, C Jacquillat, Marie-Françoise Auclerc and Y Najean. Their work appears in journals such as Recent results in cancer research, Cancer, Cancer Chemotherapy and Pharmacology, The Lancet and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.